Niacin

Sold as Wampocap, Niaspan, Niaspan Titration Starter Pack. Every FDA application for this active ingredient: 2 branded and 34 generic.

As of Nov 14, 2026, FDA lists 36 applications for Niacin (sold as Wampocap, Niaspan, Niaspan Titration Starter Pack), first approved Jul 24, 1957, with 3 new uses approved and 0 published complete response letters.

First approved: Jul 24, 1957
Applications: 36
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $10.3M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Niacin ER	Part D	$10.2M	-17%	34,527
Niacin	Part D	$98K	-79%	60
Niacor	Part D	$27K	-74%	40

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

NIACIN ER 1,000 MG TABLET: $0.324 per unitGeneric · +11% in a year
NIACIN ER 500 MG TABLET: $0.194 per unitGeneric · +20% in a year
NIACIN ER 750 MG TABLET: $0.270 per unitGeneric · -16% in a year

Clinical Trials

185 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Effectiveness and Safety of Cellbooster Hair in Healthy SubjectsHair and Scalp Health · Suisselle	Not applicable	Not yet recruiting	Nov 10, 2026
Study NRPT Feasibility in Knee OsteoarthritisKnee Osteoarthristis · University of California, San Diego	Not applicable	Recruiting	Nov 4, 2026
Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral TreatmentHIV - Human Immunodeficiency Virus · Federal University of São Paulo	Phase 2	Recruiting	Oct 29, 2026
FEAST and HOPE: Redox PSC Pilot StudyPrimary Sclerosing Cholangitis (PSC) · Brigham and Women's Hospital	Phase 2	Not yet recruiting	Oct 27, 2026
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced CardiotoxicityDoxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy · Universiti Sains Malaysia	Phase 2	Not yet recruiting	Oct 27, 2026
Combined Metabolic Activator Supplementation in Subjects Diagnosed With GoutGout Disease · ScandiBio Therapeutics AB	Phase 3	Not yet recruiting	Oct 22, 2026
COMPARISON OF TOPICAL VITAMIN C VS NIACINAMIDE IN TREATMENT OF MELASMAMelasma · Pak Emirates Military Hospital	Not applicable	Not yet recruiting	Oct 22, 2026
Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy AdultsNAD+ Metabolism, Pharmacokinetics · dsm-firmenich Switzerland AG	Phase 1	Recruiting	Oct 19, 2026

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jul 24, 1957	WampocapNDA 11073 · New combination	Medpointe Pharm Hlc	0	Discontinued
Sep 15, 1972	NiacinANDA 83180	Ivax Sub Teva Pharms	0	Discontinued
Jan 4, 1973	NiacinANDA 83136	Watson Labs	0	Discontinued
Aug 1, 1973	NiacinANDA 83525	Mk Labs	0	Discontinued
Oct 10, 1973	NiacinANDA 83305	Watson Labs	2	Discontinued
Nov 26, 1973	NicolarANDA 83823	Sanofi Aventis US	2	Discontinued
Jan 7, 1974	NiacinANDA 83718	Hikma	3	Discontinued
Apr 28, 1992	NiacinANDA 81134	Wockhardt	3	Discontinued
Jul 28, 1997	Niaspan, Niaspan Titration Starter PackNDA 20381 · New dosage form	Abbvie	31	Discontinued
May 3, 2000	NiacorANDA 40378	Avondale Pharms	3	Marketed
Apr 14, 2005	NiacinANDA 76250	Barr	3	Marketed
Apr 26, 2005	NiacinANDA 76378	Barr	4	Marketed
Mar 20, 2014	NiacinANDA 90446	Chartwell Rx	4	Marketed
Mar 20, 2014	NiacinANDA 90860	Chartwell Rx	4	Marketed
Mar 20, 2014	NiacinANDA 90892	Chartwell Rx	4	Marketed
Apr 23, 2014	NiacinANDA 200484	Sun Pharm	3	Marketed
Apr 23, 2014	NiacinANDA 201273	Sun Pharm	3	Marketed
Jul 24, 2015	NiacinANDA 203578	Amneal Pharms	0	Marketed
Dec 11, 2015	NiacinANDA 204178	Amneal Pharms	0	Marketed
Jun 16, 2017	NiacinANDA 203899	Quagen	0	Marketed
Feb 1, 2018	NiacinANDA 209236	Aurobindo Pharma Ltd	2	Marketed
May 14, 2018	NiacinANDA 209156	Jubilant Generics	0	Discontinued
Feb 22, 2019	NiacinANDA 203742	Rising	0	Discontinued
Jun 10, 2019	NiacinANDA 212017	Yichang Humanwell	0	Discontinued
Nov 22, 2021	NiacinANDA 214428	Beijing	1	Discontinued
Mar 3, 2022	NiacinANDA 204934	Macleods Pharms	2	Marketed
Aug 25, 2023	NiacinANDA 213090	Adaptis	0	Marketed
Apr 28, 2025	NiacinANDA 203285	Zydus Pharms	0	Discontinued
Jul 25, 2025	NiacinANDA 207726	Mpp Pharma	0	Marketed
—	NiacinANDA 83453	Halsey	0	Discontinued
—	NiacinANDA 83115	Impax Labs	0	Discontinued
—	NiacinANDA 83203	Everylife	0	Discontinued
—	NiacinANDA 83271	Purepac Pharm	0	Discontinued
—	NiacinANDA 83306	Sandoz	0	Discontinued
—	NiacinANDA 84237	Tablicaps	0	Discontinued
—	NiacinANDA 85172	Watson Labs	2	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA